Literature DB >> 20460879

First report on metastasizing small bowel carcinoids in first-degree relatives in three generations.

Johannes Järhult1, Kalle Landerholm, Sture Falkmer, Magnus Nordenskjöld, Frank Sundler, Nils Wierup.   

Abstract

BACKGROUND/AIMS: There is an established association between the multiple endocrine neoplasia type 1 (MEN 1) syndrome and foregut carcinoids. Some registry studies also indicate that offspring to carcinoid patients run an increased risk of developing a carcinoid tumor themselves. However, there are only scattered reports of gastrointestinal carcinoids in two generations. The aim of this study was to describe the clinical characteristics as well as the histopathological, immunohistochemical (IHC) and genetic data of metastasizing ileal carcinoids in three consecutive first-degree relatives.
METHODS: The histopathological and IHC analyses were performed on newly cut sections of the tumor specimens and included growth pattern, proliferation index (Ki-67) as well as expression of established neuroendocrine markers and recently introduced cocaine-amphetamine-regulated transcript (CART). The genetic analyses were focused on establishing whether a connection with the MEN 1 syndrome existed in this family, by means of mutation screening using polymerase chain reaction, multiple ligation-dependent probe amplification, and genotyping using fluorescent-labeled microsatellite markers.
RESULTS: Histopathology and IHC revealed that the tumors were virtually identical, with only minor differences in proliferation index and expression of CART. Genetic analyses indicated that the inheritance of the small bowel carcinoids in the family was not linked to the MEN1 gene.
CONCLUSION: Metastasizing small bowel carcinoids have been found in first-degree relatives in three consecutive generations. All three tumors were very similar when characterized by histopathology and IHC. Based on clinical findings and genetic analyses, it seems unlikely, although not completely excluded, that inheritance was linked to the MEN 1 syndrome. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460879     DOI: 10.1159/000299790

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  11 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

2.  Overrepresentation of HLA-DQ2 in small intestinal neuroendocrine tumor patients.

Authors:  Kalle Landerholm; Ursula Falkmer; Roland Persson; Najme Wall; Claes Hallert; Johannes Järhult
Journal:  J Gastrointest Cancer       Date:  2014-12

3.  Genetic associations with sporadic neuroendocrine tumor risk.

Authors:  Monica Ter-Minassian; Zhaoxi Wang; Kofi Asomaning; Michael C Wu; Chen-Yu Liu; Jessica K Paulus; Geoffrey Liu; Penelope A Bradbury; Rihong Zhai; Li Su; Christine S Frauenhoffer; Susanne M Hooshmand; Immaculata De Vivo; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Carcinogenesis       Date:  2011-05-23       Impact factor: 4.944

4.  A Hereditary Form of Small Intestinal Carcinoid Associated With a Germline Mutation in Inositol Polyphosphate Multikinase.

Authors:  Yoshitatsu Sei; Xilin Zhao; Joanne Forbes; Silke Szymczak; Qing Li; Apurva Trivedi; Mark Voellinger; Grishma Joy; Jianying Feng; Millie Whatley; MaryPat Sussex Jones; Ursula L Harper; Stephen J Marx; Aradhana M Venkatesan; Settara C Chandrasekharappa; Mark Raffeld; Martha M Quezado; Adeline Louie; Clara C Chen; Ramona M Lim; Richa Agarwala; Alejandro A Schäffer; Marybeth S Hughes; Joan E Bailey-Wilson; Stephen A Wank
Journal:  Gastroenterology       Date:  2015-04-09       Impact factor: 22.682

Review 5.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

6.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

Review 7.  Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

Authors:  Ashley Kieran Clift; Mark Kidd; Lisa Bodei; Christos Toumpanakis; Richard P Baum; Kjell Oberg; Irvin M Modlin; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 5.135

8.  A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors.

Authors:  Jan P Dumanski; Chiara Rasi; Peyman Björklund; Hanna Davies; Abir S Ali; Malin Grönberg; Staffan Welin; Halfdan Sorbye; Henning Grønbæk; Janet L Cunningham; Lars A Forsberg; Lars Lind; Erik Ingelsson; Peter Stålberg; Per Hellman; Eva Tiensuu Janson
Journal:  Endocr Relat Cancer       Date:  2017-06-20       Impact factor: 5.678

Review 9.  Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.

Authors:  Mark Kidd; Irvin M Modlin; Lisa Bodei; Ignat Drozdov
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-01-12

10.  Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization.

Authors:  Jamileh Hashemi; Omid Fotouhi; Luqman Sulaiman; Magnus Kjellman; Anders Höög; Jan Zedenius; Catharina Larsson
Journal:  BMC Cancer       Date:  2013-10-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.